蒙药平喘灵胶囊治疗支气管哮喘患者的临床研究

Clinical trial of Mongolian medicine Pingchuanling capsule in the treatment of patients with bronchial asthma

目的 研究蒙药平喘灵胶囊对支气管哮喘患者临床疗效及其白细胞介素-4(IL-4)、白细胞介素-6(IL-6)及白细胞介素-10(IL-10)水平的影响。方法 将60例患者随机分为试验组及对照组,各30例。对照组给予咳喘宁胶囊,每次2.0 g,每日2次,口服,疗程为4周;试验组给予平喘灵胶囊,每次1.4 g,每日2次,口服,疗程为4周。通过蒙医证候评分、测定肺功能及流式细胞仪测定IL-4、IL-6、IL-10水平,分析蒙药平喘灵胶囊治疗支气管哮喘临床疗效及其机制。结果 治疗后,试验组和对照组的总有效率分别为83.33%(25例/30例)和80.00%(24例/30例),差异无统计学意义(P>0.05)。治疗后,试验组和对照组的用力肺活量(FVC)分别为(3.29±0.09)和(3.20±0.12)L,第一秒用力呼气量(FEV1)分别为(2.31±0.14)和(2.25±0.11)L,第一秒呼气容积占用力肺活量比值(FEV1/FVC)分别为70.26±0.05和70.46±0.04,呼气峰流量(PEF)分别为(5.65±0.16)和(5.68±0.17) L·s^(-1);IL-4分别为(0.81±0.19)和(0.87±0.13) pg·mL^(-1),IL-6分别为(5.15±0.45)和(2.64±0.40) pg·mL^(-1),IL-10分别为(3.46±0.29)和(2.54±0.20) pg·mL^(-1),差异均有统计学意义(均P<0.05)。结论 蒙药平喘灵胶囊控制支气管哮喘疗效较好,疗效机制可能是通过调节血清白细胞介素-4、白细胞介素-6、白细胞介素-10发挥作用。

Objective To study the clinical efficacy of Mongolian medicine Pingchuanling capsules on patients with bronchial asthma and its effect on the levels of interleukin-4 (IL-4) ,interleukin-6 (IL -6) and interleukin-10 (IL-10) . Methods The 60 patients were randomly divided into treatment group and control group,30 cases in each. Control group was given Kechuanning capsules,2. 0 g each time,twice a day,orally for 4 weeks;treatment group was given Pingchuanling capsules,1. 4 g each time,twice a day,orally,for a course of 4 weeks.The clinical efficacy and mechanism of Mongolian medicine Pingchuanling capsule in the treatment of bronchial asthma were analyzed by Mongolian medicine syndrome score,determination of lung function and flow cytometry to measure the levels of IL-4,IL-6 and IL-10.Results After treatment,the total effective rates of treatment group and control group were 83. 33% (25 cases /30 cases) and 80. 00% (24 cases /30 cases) ,the difference was not statistically significant (P > 0. 05) . After treatment,the forced vital capacity (FVC) of treatment group and control group were (3. 29±0. 09) and (3. 20±0. 12) L,respectively;and the forced expiratory volume in one second(FEV1) were (2. 31±0. 14) and (2. 25±0. 11) L,respectively;FEV1 /FVC were 70. 26±0. 05 and 70. 46±0. 04,respectively;the peak expiratory flow (PEF) were (5. 65±0. 16) and (5. 68±0. 17) L·s^(-1),respectively;IL-4were (0. 81±0. 19) and (0. 87±0. 13) pg ·m L^(-1);IL-6 were (5. 15±0. 45) and (2. 64±0. 40) pg·m L^(-1),respectively;and IL-10 were (3. 46±0. 29) and (2. 54±0. 20) pg·m L^(-1),respectively;and the differences were statistically significant (all P < 0. 05) . Conclusion Mongolian medicine Pingchuanling capsule has better curative effect in controlling bronchial asthma,and its therapeutic mechanism may be through regulating serum interleukin-4,interleukin-6 and interleukin-10.